Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas

Standard

Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. / Heinzelmann, F; Bethge, W; Beelen, D W; Engelhard, M; Kröger, Nicolaus; Dreger, P; Niederwieser, D; Finke, J; Bunjes, D; Tischer, J; Kobbe, G; Holler, E; Bornhäuser, M; Stelljes, M; Baurmann, H; Müller, A; Haubitz, I; Schrezenmeier, H; Müller, C; Ottinger, H.

in: BONE MARROW TRANSPL, Jahrgang 51, Nr. 5, 05.2016, S. 654-62.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Heinzelmann, F, Bethge, W, Beelen, DW, Engelhard, M, Kröger, N, Dreger, P, Niederwieser, D, Finke, J, Bunjes, D, Tischer, J, Kobbe, G, Holler, E, Bornhäuser, M, Stelljes, M, Baurmann, H, Müller, A, Haubitz, I, Schrezenmeier, H, Müller, C & Ottinger, H 2016, 'Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas', BONE MARROW TRANSPL, Jg. 51, Nr. 5, S. 654-62. https://doi.org/10.1038/bmt.2015.348

APA

Heinzelmann, F., Bethge, W., Beelen, D. W., Engelhard, M., Kröger, N., Dreger, P., Niederwieser, D., Finke, J., Bunjes, D., Tischer, J., Kobbe, G., Holler, E., Bornhäuser, M., Stelljes, M., Baurmann, H., Müller, A., Haubitz, I., Schrezenmeier, H., Müller, C., & Ottinger, H. (2016). Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. BONE MARROW TRANSPL, 51(5), 654-62. https://doi.org/10.1038/bmt.2015.348

Vancouver

Bibtex

@article{127e175287094c3fa56ca1f5dca79259,
title = "Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas",
abstract = "Allogeneic hematopoietic cell transplantation (HCT) offers the chance of cure for patients with non-transformed follicular lymphoma (FL), but is associated with the risk of non-relapse mortality (NRM). The aim of this study was to identify subgroups of FL patients who benefit from HCT. The European Society for Blood and Marrow Transplantation (EBMT) Minimum-Essential-A Data of 146 consecutive patients who received HCT for FL between 1998 and 2008 were extracted from the database of the German Registry 'DRST'. Diagnosis of FL was verified by contact with the reference pathologists. Estimated 1-, 2- and 5-year overall survivals (OS) were 67%, 60% and 53%, respectively. Day 100 NRM was 15%. Thirteen out of 33 patients (40%) with treatment-refractory disease (RD) at the time of transplantation survived long term. Univariate statistical analysis suggested limited chronic GvHD, donor age ⩽42 years and TBI-based conditioning in treatment refractory patients to correlate with favorable OS. Independent prognostic factors for OS were treatment-sensitive disease and limited chronic GvHD for the whole cohort, and additionally TBI-based conditioning for the treatment refractory subgroup. In contrast, patient age ⩾55 years had no impact on outcome. Thus, HCT for FL is associated with acceptable NRM, and offers a substantial chance of cure for patients with RD or advanced age. Donors ⩽42 years should be preferred if available.Bone Marrow Transplantation advance online publication, 8 February 2016; doi:10.1038/bmt.2015.348.",
author = "F Heinzelmann and W Bethge and Beelen, {D W} and M Engelhard and Nicolaus Kr{\"o}ger and P Dreger and D Niederwieser and J Finke and D Bunjes and J Tischer and G Kobbe and E Holler and M Bornh{\"a}user and M Stelljes and H Baurmann and A M{\"u}ller and I Haubitz and H Schrezenmeier and C M{\"u}ller and H Ottinger",
year = "2016",
month = may,
doi = "10.1038/bmt.2015.348",
language = "English",
volume = "51",
pages = "654--62",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "5",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas

AU - Heinzelmann, F

AU - Bethge, W

AU - Beelen, D W

AU - Engelhard, M

AU - Kröger, Nicolaus

AU - Dreger, P

AU - Niederwieser, D

AU - Finke, J

AU - Bunjes, D

AU - Tischer, J

AU - Kobbe, G

AU - Holler, E

AU - Bornhäuser, M

AU - Stelljes, M

AU - Baurmann, H

AU - Müller, A

AU - Haubitz, I

AU - Schrezenmeier, H

AU - Müller, C

AU - Ottinger, H

PY - 2016/5

Y1 - 2016/5

N2 - Allogeneic hematopoietic cell transplantation (HCT) offers the chance of cure for patients with non-transformed follicular lymphoma (FL), but is associated with the risk of non-relapse mortality (NRM). The aim of this study was to identify subgroups of FL patients who benefit from HCT. The European Society for Blood and Marrow Transplantation (EBMT) Minimum-Essential-A Data of 146 consecutive patients who received HCT for FL between 1998 and 2008 were extracted from the database of the German Registry 'DRST'. Diagnosis of FL was verified by contact with the reference pathologists. Estimated 1-, 2- and 5-year overall survivals (OS) were 67%, 60% and 53%, respectively. Day 100 NRM was 15%. Thirteen out of 33 patients (40%) with treatment-refractory disease (RD) at the time of transplantation survived long term. Univariate statistical analysis suggested limited chronic GvHD, donor age ⩽42 years and TBI-based conditioning in treatment refractory patients to correlate with favorable OS. Independent prognostic factors for OS were treatment-sensitive disease and limited chronic GvHD for the whole cohort, and additionally TBI-based conditioning for the treatment refractory subgroup. In contrast, patient age ⩾55 years had no impact on outcome. Thus, HCT for FL is associated with acceptable NRM, and offers a substantial chance of cure for patients with RD or advanced age. Donors ⩽42 years should be preferred if available.Bone Marrow Transplantation advance online publication, 8 February 2016; doi:10.1038/bmt.2015.348.

AB - Allogeneic hematopoietic cell transplantation (HCT) offers the chance of cure for patients with non-transformed follicular lymphoma (FL), but is associated with the risk of non-relapse mortality (NRM). The aim of this study was to identify subgroups of FL patients who benefit from HCT. The European Society for Blood and Marrow Transplantation (EBMT) Minimum-Essential-A Data of 146 consecutive patients who received HCT for FL between 1998 and 2008 were extracted from the database of the German Registry 'DRST'. Diagnosis of FL was verified by contact with the reference pathologists. Estimated 1-, 2- and 5-year overall survivals (OS) were 67%, 60% and 53%, respectively. Day 100 NRM was 15%. Thirteen out of 33 patients (40%) with treatment-refractory disease (RD) at the time of transplantation survived long term. Univariate statistical analysis suggested limited chronic GvHD, donor age ⩽42 years and TBI-based conditioning in treatment refractory patients to correlate with favorable OS. Independent prognostic factors for OS were treatment-sensitive disease and limited chronic GvHD for the whole cohort, and additionally TBI-based conditioning for the treatment refractory subgroup. In contrast, patient age ⩾55 years had no impact on outcome. Thus, HCT for FL is associated with acceptable NRM, and offers a substantial chance of cure for patients with RD or advanced age. Donors ⩽42 years should be preferred if available.Bone Marrow Transplantation advance online publication, 8 February 2016; doi:10.1038/bmt.2015.348.

U2 - 10.1038/bmt.2015.348

DO - 10.1038/bmt.2015.348

M3 - SCORING: Journal article

C2 - 26855152

VL - 51

SP - 654

EP - 662

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 5

ER -